

MEETING ABSTRACT

Open Access

PW01-033 – Phenotype – genotype in Armenian children with FMF

G Amaryan^{1*}, T Sarkissian², T Sarkissian², H Hayrapetyan², H Hayrapetyan², A Tadevosyan³

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switerland. 22-26 May 2013

Introduction

Familial Mediterranean Fever (FMF) is an ethnic disease for Armenian population and represents a significant health care problem. Frequency of carriers of *MEFV* mutations is 1:3, and the prevalence of FMF is rather high (14-100:10000). During the period between 2003 and 2012 there was a 4.5-fold increase of the total number of children with FMF. Many of these cases have severe clinical picture and atypical course, which may complicate timely diagnosis.

Objectives

To establish phenotype-genotype correlations in Armenian children with FMF

Methods


We analyzed a group of 715 children with FMF (438 boys and 277 girls, mean age: 8.64 ± 0.17), including sporadic (51.8%) and familial cases (48.2%). The diagnosis was based on the Tel-Hashomer criteria, the "Guidelines for the genetic diagnosis of hereditary recurrent fevers"(2011) and molecular-genetic detection of 12~MEFV mutations common for Armenians. The statistical analysis was performed using Epi-Info 2000 software. For comparison of two nominal variables in table "two by two" Yaet's corrected for continuity chi-square test was used, significance level p<0.05.

Results

FMF manifestation during the first decade of life were determined in 95.2% of patients (mean age of onset 3.5 ± 0.1 , mean age of diagnosis 5.25 ± 0.15). FMF onset before 5 years was in 78.6%. In 96.5% of patients severe phenotype

¹National Pediatric Centre for Familial Mediterranean Fever of "Arabkir" Joint Medical Centre - Institute of Child and Adolescent Health, Yerevan State Medical University, Armenia

Full list of author information is available at the end of the article



Among concurrent pathologies, we found Henoch-Shonlein purpura (HSP,1.5%), protracted febrile myalgia (PFM, 2.7%) as well as the higher than expected frequencies for juvenile idiopathic arthritis (JIA, 4.7%), non-amyloid renal involvements (NARI, 1.1%) and ulcerative colitis/Crohn's disease (UC/CD, 1%). The development of serositis, splenomegaly, ELE and vasculitis was associated with M694 homozygous and compound-heterozygous genotypes. Early manifestation and severe FMF attacks were detected in patients carrying M694Vgenotypes, whereas the M680I and V726A mutations were associated with relatively mild clinical features. Adhesive intestinal obstruction (AIO), was detected in 3.2% of patients, in some cases as the first and only FMF manifestation, especially in the M694Vcarriers.

Conclusion

Taking into account the high prevalence of FMF in Armenia, *MEFV* mutation screening is recommended not only for patients with atypical symptoms resembling FMF, but also for patients with FMF- associated vasculitis (HSP, PFM) as well as co-existed immune diseases (JIA, NARI, UC/CD) and AIO. In addition to improving the early diagnosis of FMF and preventing the development of amyloidosis, this can be especially important in the patients resistant to conventional treatments for the aforementioned FMF-associated and other concurrent diseases.



Disclosure of interest

None declared.

Authors' details

¹National Pediatric Centre for Familial Mediterranean Fever of "Arabkir" Joint Medical Centre - Institute of Child and Adolescent Health, Yerevan State Medical University, Armenia. ²Centre of Medical Genetics and Primary Health Care, Yerevan, Armenia. ³Yerevan State Medical University, Yerevan, Armenia.

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A86

Cite this article as: Amaryan et al.: PW01-033 – Phenotype – genotype in Armenian children with FMF. Pediatric Rheumatology 2013 11(Suppl 1):

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

